Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

WP1130 Inhibits Signaling through BCR-ABL Ubiquitination and Cytoplasmic to Aggresome Trafficking to Induce Apoptosis of CML Cells.

Nicholas J Donato, Ph.D., Hanshi Sun, Ph.D., Vaibhav Kapuria, Luke F Peterson, PhD, Geoffrey Bartholomeusz, Ph.D., William G. Bornmann, Ph.D., Moshe Talpaz, M.D.

Blood (2009) 114 (22): 3303.

https://doi.org/10.1182/blood.V114.22.3303.3303

Published: 2009

Journal Articles

Sequencing of Subcloned PCR Products Facilitates Earlier Detection of BCR-ABL1 T315I Mutants Compared to Direct Sequencing of the ABL1 Kinase Domain.

Alfonso Quintás-Cardama, MD, Don L. Gibbons, M.D., Ph.D., Hagop Kantarjian, M.D., Moshe Talpaz, M.D., Nicholas Donato, Ph.D., Jorge Cortes, M.D.

Blood (2007) 110 (11): 1952.

https://doi.org/10.1182/blood.V110.11.1952.1952

Published: 2007

Journal Articles

Mutations within BCR-ABL1 295–312 Define a Novel Region Associated with Poor Prognosis in Patients with Chronic Myelogenous Leukemia (CML) Resistant to Imatinib.

Alfonso Quintás-Cardama, MD, Don L. Gibbons, M.D., Ph.D., Hagop Kantarjian, M.D., Moshe Talpaz, M.D., Jorge Cortes, M.D., Nicholas Donato, Ph.D.

Blood (2007) 110 (11): 1936.

https://doi.org/10.1182/blood.V110.11.1936.1936

Published: 2007

Journal Articles

Mutational Analysis of Chronic Myeloid Leukemia (CML) Clones Reveals Heightened BCR-ABL1 Genetic Instability and Wild-Type BCR-ABL1 Exhaustion in Patients Failing Sequential Imatinib and Dasatinib Therapy.

Alfonso Quintás-Cardama, MD, Don L. Gibbons, M.D., Ph.D., Hagop Kantarjian, M.D., Moshe Talpaz, M.D., Nick Donato, Ph.D., Jorge Cortes, M.D.

Blood (2007) 110 (11): 1938.

https://doi.org/10.1182/blood.V110.11.1938.1938

Published: 2007

Journal Articles

Inhibition of JAK2/STAT Signaling by Degrasyn through a Novel Mechanism.

Vaibhav Kapuria, MS, Geoffrey Bartholomeusz, Ph.D., William Bornmann, Ph.D., Ling Y. Kong, M.D., Moshe Talpaz, M.D., Nicholas J. Donato, Ph.D.

Blood (2006) 108 (11): 3423.

https://doi.org/10.1182/blood.V108.11.3423.3423

Published: 2006

Journal Articles

Activity of ABL Kinase Inhibitors in Two Distinct Models of Imatinib Resistance.

Nicholas J. Donato, PhD, Ji Wu, M.D., William Bornmann, Ph.D., Moshe Talpaz, M.D.

Blood (2006) 108 (11): 4819.

https://doi.org/10.1182/blood.V108.11.4819.4819

Published: 2006

Journal Articles

Lyn Kinase Alters Gab2 Phosphorylation and c-Cbl Protein Levels To Regulate Imatinib Sensitivity and Survival of Chronic Myelogenous Leukemia Cells.

Ji Wu, MD, Feng Meng, M.D., Moshe Talpaz, M.D., Nicholas J. Donato, PhD

Blood (2006) 108 (11): 2132.

https://doi.org/10.1182/blood.V108.11.2132.2132

Published: 2006

Journal Articles

High-Dose Imatinib Mesylate Treatment in Patients (Pts) with Previously Untreated Early Chronic Phase (CP) Chronic Myeloid Leukemia (CML).

Jorge Cortes, M.D., Moshe Talpaz, M.D., Susan O’Brien, M.D., Francis Giles, M.D., Mary Beth Rios, R.N., Laurie Levtak, M.D., Hagop Kantarjian, M.D.

Blood (2004) 104 (11): 999.

https://doi.org/10.1182/blood.V104.11.999.999

Published: 2004

Journal Articles

Clinical Significance of Molecular Monitoring in Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Imatinib Therapy.

Jorge Cortes, M.D., Moshe Talpaz, M.D., Susan O’Brien, M.D., Dan Jones, M.D., Ph.D., Raja Luthra, Ph.D., Guillermo Garcia-Manero, M.D., Francis Giles, M.D., Jenny Shan, Ph.D., Srdan Verstovsek, M.D., Ph.D., Mary Beth Rios, R.N., Hagop Kantarjian, M.D.

Blood (2004) 104 (11): 272.

https://doi.org/10.1182/blood.V104.11.272.272

Published: 2004

Journal Articles

Significance of Marrow Fibrosis in Chronic Phase Chronic Myelogenous Leukemia (CML) Post Interferon-A Failure Treated with Imatinib Mesylate Therapy.

Ricardo H. Alvarez, M.D., Hagop M. Kantarjian, M.D., Carlos Bueso-Ramos, M.D., PhD, Moshe Talpaz, M.D., Susan O’Brien, M.D., Francis Giles, M.D., Mary Beth Rios, Jianqin Shan, PhD, Jorge Cortes, M.D.

Blood (2004) 104 (11): 2939.

https://doi.org/10.1182/blood.V104.11.2939.2939

Published: 2004

Journal Articles

Hypomethylation Dynamics Following Decitabine Therapy in Chronic Myelogenous Leukemia.

Jean-Pierre J. Issa, M.D., Vazganush Gharibyan, Ph.D., Jaroslav Jelinek, M.D., Ph.D., Gail Morris, RN, Srdan Verstovsek, M.D., Moshe Talpaz, M.D., Guillermo Garcia-Manero, M.D., Hagop M. Kantarjian, M.D.

Blood (2004) 104 (11): 2956.

https://doi.org/10.1182/blood.V104.11.2956.2956

Published: 2004

Journal Articles

Survival Advantage for Patients (pts) with Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) Treated with Imatinib.

Jorge Cortes, M.D., Moshe Talpaz, M.D., Susan O’Brien, M.D., Guillermo Garcia-Manero, M.D., Farhad Ravandi-Kashami, M.D., Francis Giles, M.D., Stefan Faderl, M.D., William Wierda, M.D., Jianqin Shan, Ph.D., Mary Beth Rios, R.N., Hagop Kantarjian, M.D.

Blood (2004) 104 (11): 1006.

https://doi.org/10.1182/blood.V104.11.1006.1006

Published: 2004

Journal Articles

Phase I Study of Lonafarnib (SCH66336) in Combination with Imatinib for Patients (Pts) with Chronic Myeloid Leukemia (CML) after Failure to Imatinib.

Jorge Cortes, M.D., Susan O’Brien, M.D., Srdan Verstovsek, M.D., George Daley, M.D., Charles Koller, M.D., Alessandra Ferrajoli, M.D., Odeal Pate, R.N., Stefan Faderl, M.D., Farhad Ravandi-Kashani, M.D., Moshe Talpaz, M.D., Yali Zhu, Ph.D., Paul Statkevich, Ph.D., Mary Sugrue, M.D., Hagop Kantarjian, M.D.

Blood (2004) 104 (11): 1009.

https://doi.org/10.1182/blood.V104.11.1009.1009

Published: 2004

Journal Articles

A Phase I Study of Tipifarnib in Combination with Imatinib Mesylate (IM) for Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Who Failed IM Therapy.

Jorge Cortes, M.D., Guillermo Garcia-Manero, M.D., Susan O’Brien, M.D., Ingrid Hernandez, R.N., Wayne Rackoff, M.D., Stefan Faderl, M.D., Deborah Thomas, M.D., Alessandra Ferrajoli, M.D., Moshe Talpaz, M.D., Hagop Kantarjian, M.D.

Blood (2004) 104 (11): 1011.

https://doi.org/10.1182/blood.V104.11.1011.1011

Published: 2004

Journal Articles

Is the Proposed World Health Organization (WHO) Classification for Chronic Myeloid Leukemia (CML) of Clinical Value in the Imatinib Era?.

Jorge Cortes, M.D., Susan O’Brien, M.D., Guillermo Garcia-Manero, M.D., Stefan Faderl, M.D., Jenny Shan, Ph.D., Francis Giles, M.D., Srdan Verstovsek, M.D., Mary Beth Rios, R.N., Moshe Talpaz, M.D., Hagop Kantarjian, M.D.

Blood (2004) 104 (11): 1014.

https://doi.org/10.1182/blood.V104.11.1014.1014

Published: 2004

Journal Articles

WP-1066, a Next-Generation Member of JAK-Stat Inhibitors, Induces Cell Cycle Arrest, Abrogates Proliferation, and Induces Apoptosis of Acute Myeloid Leukemia (AML) Cells.

Alessandra Ferrajoli, M.D., Stefan Faderl, M.D., Quin Van, B.S., David M. Harris, B.S., Waldemar Priebe, Ph.D., Hagop M. Kantarjian, M.D., Moshe Talpaz, M.D., Zeev Estrov, M.D.

Blood (2004) 104 (11): 1169.

https://doi.org/10.1182/blood.V104.11.1169.1169

Published: 2004

Journal Articles

Effects of Adaphostin, a Novel Tyrphostin Inhibitor, in Diverse Models of Imatinib Mesylate Resistance.

Joya Chandra, Ph.D., Jeannette Tracy, Mercedes Gorre, Ph.D., Moshe Talpaz, M.D., James Griffin, M.D., Srdan Verstovsek, M.D., Ph.D., Miloslav Beran, M.D., Charles Sawyers, M.D., Edward Sausville, M.D., Scott Kaufmann, M.D., Ph.D.

Blood (2004) 104 (11): 2097.

https://doi.org/10.1182/blood.V104.11.2097.2097

Published: 2004

Journal Articles

The SRC/ABL Inhibitor BMS-354825 Overcomes Resistance to Imatinib Mesylate in Chronic Myelogenous Leukemia Cells through Multiple Mechanisms.

Nicholas J. Donato, Ph.D., Ji Wu, M.D., Ling Y. Kong, Ph.D., M.D., Francis Lee, Ph.D., Moshe Talpaz, M.D.

Blood (2004) 104 (11): 1989.

https://doi.org/10.1182/blood.V104.11.1989.1989

Published: 2004

Journal Articles

PEG-Intron for Myeloproliferative Diseases: An Update of Ongoing Phase II Study.

Srdan Verstovsek, M.D., Ph.D., Kristie Lawhorn, BCLS, R.N., Francis Giles, M.D., Jorge Cortes, M.D., Deborah Thomas, M.D., Guillermo Garcia-Manero, M.D., Alessandra Ferrajoli, M.D., Stefan Faderl, M.D., Miloslav Beran, M.D., Ph.D., Moshe Talpaz, M.D., Hagop Kantarjian, M.D.

Blood (2004) 104 (11): 1517.

https://doi.org/10.1182/blood.V104.11.1517.1517

Published: 2004

NARROW

WP1130 Inhibits Signaling through BCR-ABL Ubiquitination and Cytoplasmic to Aggresome Trafficking to Induce Apoptosis of CML Cells.

Sequencing of Subcloned PCR Products Facilitates Earlier Detection of BCR-ABL1 T315I Mutants Compared to Direct Sequencing of the ABL1 Kinase Domain.

Mutations within BCR-ABL1 295–312 Define a Novel Region Associated with Poor Prognosis in Patients with Chronic Myelogenous Leukemia (CML) Resistant to Imatinib.

Mutational Analysis of Chronic Myeloid Leukemia (CML) Clones Reveals Heightened BCR-ABL1 Genetic Instability and Wild-Type BCR-ABL1 Exhaustion in Patients Failing Sequential Imatinib and Dasatinib Therapy.

Inhibition of JAK2/STAT Signaling by Degrasyn through a Novel Mechanism.

Activity of ABL Kinase Inhibitors in Two Distinct Models of Imatinib Resistance.

Lyn Kinase Alters Gab2 Phosphorylation and c-Cbl Protein Levels To Regulate Imatinib Sensitivity and Survival of Chronic Myelogenous Leukemia Cells.

High-Dose Imatinib Mesylate Treatment in Patients (Pts) with Previously Untreated Early Chronic Phase (CP) Chronic Myeloid Leukemia (CML).

Clinical Significance of Molecular Monitoring in Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Imatinib Therapy.

Significance of Marrow Fibrosis in Chronic Phase Chronic Myelogenous Leukemia (CML) Post Interferon-A Failure Treated with Imatinib Mesylate Therapy.

Hypomethylation Dynamics Following Decitabine Therapy in Chronic Myelogenous Leukemia.

Survival Advantage for Patients (pts) with Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) Treated with Imatinib.

Phase I Study of Lonafarnib (SCH66336) in Combination with Imatinib for Patients (Pts) with Chronic Myeloid Leukemia (CML) after Failure to Imatinib.

A Phase I Study of Tipifarnib in Combination with Imatinib Mesylate (IM) for Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Who Failed IM Therapy.

Is the Proposed World Health Organization (WHO) Classification for Chronic Myeloid Leukemia (CML) of Clinical Value in the Imatinib Era?.

WP-1066, a Next-Generation Member of JAK-Stat Inhibitors, Induces Cell Cycle Arrest, Abrogates Proliferation, and Induces Apoptosis of Acute Myeloid Leukemia (AML) Cells.

Effects of Adaphostin, a Novel Tyrphostin Inhibitor, in Diverse Models of Imatinib Mesylate Resistance.

The SRC/ABL Inhibitor BMS-354825 Overcomes Resistance to Imatinib Mesylate in Chronic Myelogenous Leukemia Cells through Multiple Mechanisms.

PEG-Intron for Myeloproliferative Diseases: An Update of Ongoing Phase II Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only